Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02503423
Recruitment Status : Active, not recruiting
First Posted : July 21, 2015
Last Update Posted : April 20, 2020
Sponsor:
Information provided by (Responsible Party):
Astex Pharmaceuticals, Inc.

Brief Summary:
This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for whom standard life-prolonging measures are not available.

Condition or disease Intervention/treatment Phase
Solid Tumors Lymphoma Drug: ASTX660 Phase 1 Phase 2

Detailed Description:
ASTX660 is a synthetic small molecule dual antagonist of cellular inhibitor of apoptosis protein (cIAP) 1 and X-linked inhibitor of apoptosis protein (XIAP) that has been shown to have potent proapoptotic and tumor growth inhibitory activity in nonclinical models. The Phase 1 portion of the study will determine the MTD, RP2D, and recommended dosing regimen. The Phase 2 portion will evaluate activity in selected tumor types. Subjects will continue to receive their assigned treatment throughout the study until the occurrence of disease progression, death, or unacceptable treatment-related toxicity, or until the study is closed by the sponsor.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Study Start Date : July 2015
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : October 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Phase 1 - Part 1
Dose-escalation stage to identify the MTD and the RP2D, defined as either the MTD or a dose below the MTD that the Data and Safety Review Committee (DSRC) agree shows adequate pharmacological evidence of target engagement and/or clinical activity. Subjects will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, [7 days on/ 7 days off] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RP2D is determined.
Drug: ASTX660
described above
Other Name: Treatment of ASTX660 for advanced solid tumors and lymphomas

Experimental: Phase 1 - Part 2
Dose-expansion stage to confirm tolerability of ASTX660 at the RP2D using the every-other-week daily dosing regimen. Up to a total of 12 subjects (including the 3 or 6 subjects treated at the RP2D in Part 1) will be treated at the RP2D.
Drug: ASTX660
described above
Other Name: Treatment of ASTX660 for advanced solid tumors and lymphomas

Experimental: Phase 1 - Part 3 (optional)
The purpose of the optional Part 3 is to allow for exploration of an alternative dosing regimen of ASTX660 based on emerging safety, PK, and pharmacodynamic (PD) data from Parts 1 and 2 (using the original every-other-week dosing regimen), with agreement of the DSRC. If Part 3 is conducted, the plan is to enroll up to 18 evaluable subjects in 1 or more cohorts using a standard 3+3 study design.
Drug: ASTX660
described above
Other Name: Treatment of ASTX660 for advanced solid tumors and lymphomas

Experimental: Phase 2 - Cohort 1
Treatment with ASTX660 for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) not responsive or relapsed after standard therapy.
Drug: ASTX660
described above
Other Name: Treatment of ASTX660 for advanced solid tumors and lymphomas

Experimental: Phase 2 - Cohort 2
Treatment with ASTX660 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Drug: ASTX660
described above
Other Name: Treatment of ASTX660 for advanced solid tumors and lymphomas

Experimental: Phase 2 - Cohort 3
Treatment with ASTX660 for progressive or relapsed peripheral T-cell lymphoma (PTCL).
Drug: ASTX660
described above
Other Name: Treatment of ASTX660 for advanced solid tumors and lymphomas

Experimental: Phase 2 - Cohort 4
Treatment with ASTX660 for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Drug: ASTX660
described above
Other Name: Treatment of ASTX660 for advanced solid tumors and lymphomas

Experimental: Phase 2 - Cohort 5
Treatment with ASTX660 for other tumor types that are characterized by a molecular feature that may confer sensitivity to ASTX660 (eg, oncogenic activation of the NF-κB pathway or documented amplification of the gene loci encoding c-IAP1 or c-IAP2), pending confirmation in writing by the Astex medical monitor.
Drug: ASTX660
described above
Other Name: Treatment of ASTX660 for advanced solid tumors and lymphomas

Experimental: Phase 2 - Cohort 6
Treatment with ASTX660 for cervical carcinoma not responsive or relapsed after standard therapy.
Drug: ASTX660
described above
Other Name: Treatment of ASTX660 for advanced solid tumors and lymphomas




Primary Outcome Measures :
  1. Safety (Phase 1) - number of subjects with AEs, DLTs, abnormal clinical laboratory values or physical exam results [ Time Frame: Up to 78 months ]
    Incidence of dose-limiting toxicities (DLTs) and other adverse events (AEs)

  2. Efficacy (Phase 2) - antitumor activity assessed by objective response rate (ORR) [ Time Frame: Up to 78 months ]
    Antitumor activity by objective response rate

  3. Efficacy (Phase 2) - antitumor activity assessed by disease control rate (DCR) [ Time Frame: Up to 78 months ]
    Antitumor activity by disease control rate


Secondary Outcome Measures :
  1. Pharmacokinetic outcome of concentration-time curve (AUC) [ Time Frame: First 9 weeks of study treatment ]
    Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC).

  2. Pharmacokinetic outcome of maximum concentration (Cmax) [ Time Frame: First 9 weeks of study treatment ]
    Assessment of pharmacokinetic parameter maximum concentration (Cmax).

  3. Pharmacokinetic outcome of minimum concentration (Cmin) [ Time Frame: First 9 weeks of study treatment ]
    Assessment of pharmacokinetic parameter minimum concentration (Cmin).

  4. Pharmacokinetic outcome of time to maximum concentration (Tmax) [ Time Frame: First 9 weeks of study treatment ]
    Assessment of pharmacokinetic parameter time to maximum concentration (Tmax)

  5. Pharmacokinetic outcome of samples over time [ Time Frame: First 9 weeks of study treatment ]
    Assessment of pharmacokinetic parameter elimination half life (t½).

  6. Pharmacokinetic outcome of samples over time [ Time Frame: First 9 weeks of study treatment ]
    Assessment of pharmacokinetic parameter of other secondary PK parameters of ASTX660 if data permit.

  7. Pharmacokinetic outcome of analysis of ASTX660 metabolites if applicable [ Time Frame: First 9 weeks of study treatment ]
    Assessment of pharmacokinetic parameter analysis of ASTX660 metabolites if applicable.

  8. Duration of antitumor response [ Time Frame: Up to 78 months ]
    Time from the date of the earliest assessment of complete response or partial response to the date of relapse or death, whichever occurs earlier, or the last efficacy assessment date for subjects without a relapse or death.

  9. Progression-free survival [ Time Frame: Up to 78 months ]
    Number of days from the start of the study treatment to disease progression or death, whichever occurs first.

  10. Overall survival [ Time Frame: Up to 78 months ]
    Number of days from the day the subject received the first study treatment to the date of death, regardless of cause.

  11. Assessment of target (cIAP1) engagement [ Time Frame: Up to 78 months ]
    Percentage degradation of cIAP1 protein in PBMCs from baseline, in response to ASTX660 treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Able to understand and comply with the protocol and study procedures, understand the risks involved in the study, and provide written informed consent before any study-specific procedure is performed.
  2. Men and women 18 years of age or older.
  3. Subjects with histologically or cytologically confirmed advanced solid tumors or lymphoma that is metastatic or unresectable, and for whom standard life-prolonging measures are not available. Specific tumor types that will be selected for study in Phase 2 are detailed in the protocol.

    a) For Phase 2 Cohort 3, subjects must have histologically confirmed PTCL (local pathology report) as defined by 2016 World Health Organization (WHO) classification. The following subtypes are eligible for the study: adult T-cell lymphoma/leukemia, extranodal natural killer (NK)/T-cell lymphoma nasal type, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, hepatosplenic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, follicular T-cell lymphoma, nodal peripheral T-cell with T-follicular helper (THF) phenotype, and anaplastic large-cell lymphoma.

  4. For Phase 2 Cohorts 3 and 4, patients must have evidence of documented progressive disease and must have received at least two prior systemic therapies.

    1. Subjects with CD30-positive lymphoma must have received, be ineligible for, or intolerant to brentuximab vedotin.
    2. Subjects with mycosis fungoides or Sezary syndrome must have received, be ineligible or intolerant to mogamulizumab.
  5. In the Phase 2 portion of the protocol only, subjects must have measurable disease according to response criteria appropriate for their type of cancer.

    a) For Phase 2 Cohort 3 (PTCL), measurable disease by contrast-enhanced diagnostic CT (at least 1 nodal lesion ≥1.5 cm or extranodal lesions >1.0 cm) is required.

  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
  7. Acceptable organ function, as evidenced by the following laboratory data:

    1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.0 * upper limit of normal (ULN).
    2. Total serum bilirubin <=1.5 * ULN
    3. Absolute neutrophil count (ANC):

      • Phase 1 and 2 (except Phase 2 subjects with known lymphoma) >=1500 cells/mm3
      • Phase 2 subjects with known lymphoma: >=1000 cells/mm3 (>750 cell/mm3 for subjects with lymphoma in bone marrow)
    4. Platelet count:

      • Phase 1 and 2 (except Phase 2 subject with known lymphoma) >=100,000 cells/mm3
      • Phase 2 subjects with known lymphoma: >= 50,000 cells/mm3; >=25,000 cells/mm3 for subjects with lymphoma in bone marrow
    5. Serum creatinine levels <= 1.5 * ULN, or calculated (by Cockcroft-Gault formula or other accepted formula) or measure creatinine clearance >=50 mL/min.
    6. Amylase and lipase <=ULN [Applies to Phase 2].
  8. Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]; see protocol for details) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective contraceptive measures of birth control (as described in the protocol) and must agree not to become pregnant or father a child while receiving treatment with study drug and for at least 3 months after completing treatment. Contraceptive measures which may be considered highly effective comprise combined hormonal contraception (oral, vaginal, or transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, sexual abstinence, and surgically successful vasectomy. Abstinence is acceptable only if it is consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of birth control.

Exclusion Criteria:

  1. Hypersensitivity to ASTX660, excipients of the drug product, or other components of the study treatment regimen.
  2. Poor medical risk because of systemic diseases (e.g. active uncontrolled infections) in addition to the qualifying disease under study.
  3. Life-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise subject safety or the integrity of the study outcomes, or interfere with the absorption or metabolism of ASTX660.
  4. History of, or at risk for, cardiac disease, as evidenced by 1 or more of the following conditions:

    1. Abnormal left ventricular ejection fraction (LVEF; <50%) or echocardiogram ECHO or multiple gated acquisition scan (MUGA). [Applies to both Phase 1 and Phase 2.]
    2. Congestive cardiac failure of >= Grade 3 severity according to New York Heart Association (NYHA) functional classification defined as subjects with marked limitation of activity and who are comfortable only at rest.
    3. Unstable cardiac disease including angina or hypertension as defined by the need for overnight hospital admission within the last 3 months (90 days).
    4. History or presence of complete left bundle branch block, heart block, cardiac pacemaker or significant arrhythmia.
    5. Concurrent treatment with any medical that prolongs QT interval and may induce torsades de pointes, and which cannot be discontinued at least 2 weeks before treatment with ASTX660. [Applies to Phase 1 only].
    6. Personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy.
    7. Screening 12-lead ECG with measurable QTc interval (according to either Fridericia's or Bazett's correction) of >=470 msec).

    h) Any other condition that, in the opinion of the investigator, could put the subject at increased cardiac risk.

  5. Known history of human immunodeficiency virus (HIV) infection, or seropositive results consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.
  6. Grade 2 or greater neuropathy [Applies to Phase 1]. Grade 3 or greater neuropathy [Applies to Phase 2].
  7. Known brain metastases, unless stable or previously treated.
  8. Known significant mental illness or other conditions such as active alcohol or other substance abuse that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol treatment or assessments.
  9. Prior anticancer treatments or therapies within the indicated time window prior to first dose of study treatment (ASTX660), as follows:

    • Cytotoxic chemotherapy or radiotherapy within 3 weeks prior and any encountered treatment-related toxicities (excepting alopecia) not resolved to Grade 1 or less [Phase 1] or Grade 2 or less [Phase 2].
    • Skin directed treatments, including topicals and radiation within 2 weeks prior.
    • Monoclonal antibodies within 4 weeks prior and any encountered treatment-related toxicities not resolved to Grade 1 or less [Phase 1] or Grade 2 or less [Phase 2].
    • Investigational drugs (small molecules or biologics) within the longer of 2 weeks or 5 half-lives prior to study treatment and any encountered treatment-related toxicities not resolved to Grade 1 or less [Phase 1] or Grade 2 or less [Phase 2].
    • At least 6 weeks must have elapsed since CAR-T infusion and subjects must have experienced disease progression, and not have residual circulating CAR-T cells in peripheral blood (based on local assessment). Any encountered treatment-related toxicities must have resolved to Grade ≤1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02503423


Locations
Show Show 46 study locations
Sponsors and Collaborators
Astex Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Director: Jason Taylor, MD, PhD Astex Pharmaceuticals, Inc.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Astex Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02503423    
Other Study ID Numbers: ASTX660-01
First Posted: July 21, 2015    Key Record Dates
Last Update Posted: April 20, 2020
Last Verified: December 2019
Keywords provided by Astex Pharmaceuticals, Inc.:
cervical cancer
HNSCC
CTCL
PTCL
DLBCL
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases